Media
EASTGATE BIOTECH ENTERS INTO A MOU WITH GENLUICHING MINING CORP. & AAH & INTERNATIONAL ASSOCIATES INC. OF THE PHILIPPINES
March 13, 2018
WEST CALDWELL, NJ and TORONTO, March 13, 2018 (AccessNewswire-) EastGate Biotech Corp. (PinkSheets: ETBI), a pharmaceutical company that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of type 2 diabetes, is pleased to announce that has signed a Memorandum of Understanding (MOU) with Genluiching Mining Corporation (Genluiching) and AAH & International Associates (AAH), Incorporated. Within the scope of the MOU, both parties, located in the Philippines, intend to invest between PHP 100,000,000 – PHP 300,000,000 (approximately $2 million USD to $5.8 million USD) either in full or in tranches. Similar to the recently announce BuPharco Joint Venture, Genluiching and AAH will pay for all expenses related to financing as well as the clinical trials, however ETBI is expected to be the lead manager of the JV.
Read moreEASTGATE BIOTECH ANNOUNCES LICENSING/DISTRIBUTION MOU WITH BUPHARCO FOR THE INSULIN MOUTH RINSE IN THE PHILIPPINES FOR TYPE 2 DIABETES PATIENTS
March 6, 2018
ST CALDWELL, NJ and TORONTO, March 5, 2018 (AccessNewswire-) EastGate Biotech Corp. (PinkSheets: ETBI), a pharmaceutical company that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of type 2 diabetes. We are thrilled to announce today that EastGate has signed a Memorandum of Understanding (MOU) with Bukidnon Pharmaceutical Multi-Purpose Cooperatives (BuPharco). The MOU outlines the strategic plan to commercialize the oral insulin mouth rinse delivered through the buccal mucosa (inner lining of mouth) and penetrates the blood brain barrier. BuPharco will initially compile, submit, and file all dossiers to the FDA of the Philippines with the full support of EastGate’s team assisting in the compilation of the master drug file.
Read moreEASTGATE BIOTECH ANNOUNCES LICENSING/DISTRIBUTION MOU WITH BUPHARCO FOR THE INSULIN MOUTH RINSE IN THE PHILIPPINES FOR TYPE 2 DIABETES PATIENTS
March 6, 2018
WEST CALDWELL, NJ and TORONTO, March 5, 2018 (AccessNewswire-) EastGate Biotech Corp. (PinkSheets: ETBI), a pharmaceutical company that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of type 2 diabetes. We are thrilled to announce today that EastGate has signed a Memorandum of Understanding (MOU) with Bukidnon Pharmaceutical Multi-Purpose Cooperatives (BuPharco). The MOU outlines the strategic plan to commercialize the oral insulin mouth rinse delivered through the buccal mucosa (inner lining of mouth) and penetrates the blood brain barrier. BuPharco will initially compile, submit, and file all dossiers to the FDA of the Philippines with the full support of EastGate’s team assisting in the compilation of the master drug file.
Read moreEASTGATE BIOTECH PROVIDES CORPORATE UPDATE
March 1, 2018
The Company’s strategic moves over the past year to improve its underlying operations were part of a corporate vision to be a “disrupter” in the drug delivery sector targeting unmet medical needs. As a company we collectively agreed that drug development requires patience and funding and we had a realization that the burn rate needed to be curbed. The time between drug development milestones can test investor’s patience so we were opportunistic in our purchase of OMNI S
Read moreEastGate Biotech Announces Annual Report Form 10-K Filing
March 1, 2018
Toronto, ON, February 28th, 2018 – EastGate Biotech (OTC BB: ETBI) a market leading pharmaceutical technology company, today announced that it filed an Annual Report on Form 10-K under the U.S. Securities Exchange Act of 1934 for EastGate Biotech for the period through December 31, 2017 (“Form 10-K”) with the U.S. Securities Exchange Commission (the “SEC”) on 27 February 2018. The Form 10-K can be found on the SEC’s website at www.sec.gov.
Read moreEASTGATE BIOTECH ANNOUNCES OPENING OF REPRESENTATIVE OFFICE IN THE PHILIPPINES
January 29, 2018
The representative office, located in Metro Manila will be identified as EastGate Biotech Pharmaceuticals Philippines incorporated in November, 2017. In addition to providing a legal presence the office will allow EastGate Biotech to position itself in the rapidly growing and vibrant Asian healthcare market by increasing the profile of the company within this market. It will be staffed by Roger Munoz, the company’s local agent, who will serve as the Managing Director. The office will also support and coordinate all regulatory activities and serve as a hub from which EastGate management and personnel will engage its partnership strategies and new business development.
Read moreGunpowder Capital Corp. Provides Update on EastGate
December 11, 2017
Gunpowder Capital Corp. (CSE-GPC) announced today that it continues to work with its client EastGate Biotech Corp. (OTC Pink-ETBI).
Read moreEASTGATE BIOTECH ANNOUNCES ENGAGEMENT OF THE KELL GROUP LIMITED FOR INTRODUCTION TO VARIOUS SOURCES OF FUNDING FOR COMPANY INITIATIVES
August 30, 2017
“We are pleased to be working with a group that has a long standing reputation with a wide financial network," said Anna Gluskin, CEO of EastGate. “We are looking forward to moving into an exciting stage with some of our developments that have different requirements and funding strategies for which we believe The Kell Group Limited is best suited to assist in these plans and we hope will increase their shareholding position in the company”, concludes Gluskin.
Read moreEASTGATE BIOTECH’S RECENT ACQUISITION, OMNI SURGERY + ANTI-AGING CENTRE, PRESENTS THE OMNI SCHOOL OF MEDICAL ESTHETICS.
May 30, 2017
The mission statement of the OMNI School of Medical Esthetics is to ensure quality delivery of care while utilizing the latest techniques and technology. The program has two parts
Read moreEASTGATE BIOTECH CORP. ENGAGES A NEW INDEPENDENT AUDITOR
May 16, 2017
Eastgate pharmaceutical and biotech research company that develops, produces and distributes innovative and healthy nutraceuticals and pharmaceutical developments has announced today that it had selected Anton & Chia LLP as its new independent auditing firm.
Read more